Сравнение
CagriSema vs. Dulaglutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
нет данных
923950-08-7
Молекулярная масса
нет данных
59670 g/mol
Период полувыведения
нет данных
110 h
Последовательность
нет данных
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcМеханизм действия
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
5
из них на людях
1
5
Зафиксированные эффекты
2
3
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between CagriSema and Dulaglutide?
- CagriSema is classified as "Метаболизм", while Dulaglutide is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Dulaglutide?
- The highest available evidence level is "РКИ на людях" for CagriSema and "РКИ на людях" for Dulaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Dulaglutide in Germany and the United States?
- Германия: CagriSema — Не одобрено, Dulaglutide — Рецептурный. США: CagriSema — Не одобрено, Dulaglutide — Рецептурный. These are factual summaries with source and review date on the individual pages.